The long-term safety of a new asthma therapy combining fluticasone propionate and formoterol fumarate (fluticasone/formoterol; flutiform®) was assessed.
Method:
In an open-label study, mild to moderate-severe asthmatics (≥12 years; N=472) were treated twice daily with fluticasone/formoterol 100/10 μg (n=224) or 250/10 μg (n=248) for 6 months (n=256) or 12 months (n=216). The primary and secondary objectives were the long-term safety and efficacy of fluticasone/formoterol, respectively.
Results:
In total, 413 (87.5%) patients completed the study (of which 175 participated for 12 months). Adverse events (AEs) were reported by 174 patients (36.9%): 67 (29.9%) in the 100/10 μg group and 107 (43.1%) in the 250/10 μg group. The most common AEs (>2%) were nasopharyngitis, dyspnea, pharyngitis, and headache; the majority were mild to moderate. Only 18 (3.8%) patients reported AEs considered study drug–related. Five patients per group experienced 12 serious AEs; none was study medication–related. Asthma exacerbations were reported by 53 patients (11.2%): 46 mild to moderate and nine severe. Clinical laboratory tests and vital signs showed no abnormal trends or clinically important or dose-response–related changes. The efficacy analyses showed statistically significant improvements at every time point throughout the study period at both doses.
Conclusion:
Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study periods.
Get full access to this article
View all access options for this article.
References
1.
MasoliM, FabianD, HoltS, BeasleyR. Global burden of asthma, a report for the Global Initiative for Asthma. 2004. http://www.ginasthma.org. 2011January.
2.
Global Initiative for Asthma Report: GINA Report. Global strategy for asthma management and prevention. 2009. http://www.ginasthma.org. 2011January.
3.
MurphyDM, O'ByrnePM. Recent advances in the pathophysiology of asthma. Chest, 2010; 137:1417–1426.
4.
Naedele-RishaR, DorinskyP, CraigTJ. Dual components of optimal asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids. J Am Osteopath Assoc, 2001; 101:526–533.
5.
LötvallJ, AnkerstJ. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med, 2008; 102:449–456.
6.
BarnesPJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J, 2007; 29:587–595.
7.
PauwelsRA, LofdahlCG, PostmaDS, TattersfieldAE, O'ByrneP, BarnesPJ, UllmanA. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med, 1997; 337:1405–1411.
8.
GreeningAP, IndPW, NorthfieldM, ShawG. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet, 1994; 344:219–224.
9.
WoolcockA, LundbackB, RingdalN, JacquesLA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med, 1996; 153:1481–1488.
10.
O'ByrnePM, BarnesPJ, Rodriguez-RoisinR, RunnerstromE, SandstromT, SvenssonK, TattersfieldA. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med, 2001; 164,8 Pt 1:1392–1397.
11.
ThomasM, KayS, PikeJ, WilliamsA, RosenzweigJR, HillyerEV, PriceD. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J, 2009; 18:41–49.
12.
BarnesPJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J, 2002; 19:182–191.
13.
RothM, ZhongJ, S'ngC, TammM. Effect of fluticasone and formoterol combination therapy on airway remodeling. [Abstract] Presented at European Respiratory Society Congress, Amsterdam, The Netherlands, 2011. Eur Respir J, 2011; 38,Suppl 55:307s.
14.
RothM, ZhongJ, S'ngC, TammM. The long-acting β2-agonist formoterol re-establishes the anti-proliferative effect of glucocorticoids in asthmatic airway smooth muscle cells (ASMC)[Abstract] Presented at European Respiratory Society Congress, Amsterdam, The Netherlands, 2011. Eur Respir J, 2011; 38,Suppl 55:612s.
15.
UsmaniOS, ItoK, ManeechotesuwanK, ItoM, JohnsonM, BarnesPJ, AdcockIM. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med, 2005; 172:704–712.
16.
BatemanED, BrittonM, CarrilloJ, AlmeidaJ, WixonC. Salmeterol/fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma. Clin Drug Investig, 1998; 16:193–201.
17.
KavuruM, MelamedJ, GrossG, LaforceC, HouseK, PrillamanB, BaitingerL, WoodringA, ShahT. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol, 2000; 105,6 Pt 1:1108–1116.
BatemanED, BousheyHA, BousquetJ, BusseWW, ClarkTJ, PauwelsRA, PedersenSE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med, 2004; 170:836–844.
20.
O'ByrnePM, BisgaardH, GodardPP, PistolesiM, PalmqvistM, ZhuY, EkströmT, BatemanED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med, 2005; 171:129–136.
21.
HuchonG, MagnussenH, ChuchalinA, DymekL, GonodFB, BousquetJ. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med, 2009; 103:41–49.
22.
PartridgeMR, van der MolenT, MyrsethSE, BusseWW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med, 2006; 6:13.
23.
AccordiniS, BugianiM, ArossaW, GerzeliS, MarinoniA, OlivieriM, PirinaP, CarrozziL, DallariR, De TogniA, de MarcoR. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol, 2006; 141:189–198.
24.
CazzolettiL, MarconA, JansonC, CorsicoA, JarvisD, PinI, AccordiniS, AlmarE, BugianiM, CaroleiA, CerveriI, Duran-TauleriaE, GislasonD, GulsvikA, JogiR, MarinoniA, Martinez-MoratallaJ, VermeireP, de MarcoR. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol, 2007; 120:1360–1367.
25.
DemolyP, PaggiaroP, PlazaV, BolgeSC, KannanH, SohierB, AdamekL. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev, 2009; 18:105–112.
26.
VirchowJC, CromptonGK, Dal NegroR, PedersenS, MagnanA, SeidenbergJ, BarnesPJ. Importance of inhaler devices in the management of airway disease. Respir Med, 2008; 102:10–19.
27.
LeidyNK, GutierrezB, LamplK, UryniakT, O'BrienCD. Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma, 2009; 46:1006–1012.
28.
KraftM. The distal airways: are they important in asthma?Eur Respir J, 1999; 14:1403–1417.
29.
KraftM. Part III: Location of asthma inflammation and the distal airways: clinical implications. Curr Med Res Opin, 2007; 23,Suppl 3:S21–S27.
30.
BurgelPR, de BlicJ, ChanezP, DelacourtC, DevillierP, DidierA, DubusJC, FrachonI, GarciaG, HumbertM, LaurentF, LouisR, MagnanA, MahutB, PerezT, RocheN, Tillie-LeblondI, Tunon de LaraM, DusserD. Update on the roles of distal airways in asthma. Eur Respir Rev, 2009; 18:80–95.
31.
ContoliM, BousquetJ, FabbriLM, MagnussenH, RabeKF, SiafakasNM, HamidQ, KraftM. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy, 2010; 65:141–151.
32.
KetchellRI, JensenMW, SpinaD, O'ConnorBJ. Dose-related effects of formoterol on airway responsiveness to adenosine 5’-monophosphate and histamine. Eur Respir J, 2002; 19:611–616.
33.
LuijkB, KempsfordRD, WrightAM, ZanenP, LammersJ-WJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J, 2004; 23:559–564.
34.
AdamsNP, BestallJC, JonesP, LassersonTJ, GriffithsB, CatesCJ. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev, 2009; 2:CD003534.
35.
AstraZeneca UK Ltd.: Symbicort Turbohaler 100/6, Inhalation powder. Summary of Product Characteristics. 2010. http://www.medicines.org.uk/. 2011January.
36.
PolitiekMJ, BoorsmaM, AalbersR. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J, 1999; 13:988–992.
37.
PalmqvistM, ArvidssonP, BeckmanO, PetersonS, LotvallJ. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther, 2001; 14:29–34.
38.
BergerWE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol, 2006; 97:24–33.
39.
Expert Panel Report: Guidelines for the diagnosis and management of asthma: Expert Panel Report 2. National Asthma Education and Prevention Program: National Institutes of Health, National Heart Lung and Blood InstitutePublication No. 97–40511997. http://www.nhlbi.nih.gov/guidelines/asthma/. 2011.
40.
MillerMR, HankinsonJ, BrusascoV, BurgosF, CasaburiR, CoatesA, CrapoR, EnrightP, van der GrintenCP, GustafssonP, JensenR, JohnsonDC, MacIntyreN, McKayR, NavajasD, PedersenOF, PellegrinoR, ViegiG, WangerJ. Standardisation of spirometry. Eur Respir J, 2005; 26:319–338.
PolgarG, PromdhatV. Pulmonary Function Testing in Children: Techniques, Standards. W. B. Saunders Co.: Philadelphia, PA, 1971.
43.
FitzGeraldJM, BouletLP, FollowsRM. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther, 2005; 27:393–406.
44.
KunaP, PetersMJ, ManjraAI, JorupC, NayaIP, Martinez-JimenezNE, BuhlR. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract, 2007; 61:725–736.
45.
McKeageK, KeamSJ. Salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 2009; 69:1799–1828.
46.
ReynoldsNA, Lyseng-WilliamsonKA, WisemanLR. Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 2005; 65:1715–1734.
47.
RosenhallL, HeinigJH, LindqvistA, LeegaardJ, StahlE, BergqvistPB. Budesonide/formoterol (Symbicort) is well tolerated and effective in patients with moderate persistent asthma. Int J Clin Pract, 2002; 56:427–433.
48.
DhillonS, KeatingGM. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler. Drugs, 2006; 66:1475–1483discussion 1484–1475.
49.
FroisC, WuEQ, RayS, ColiceGL. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther, 2009; 31:2779–2803.
50.
LassersonTJ, CatesCJ, FerraraG, CasaliL. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev, 2010; 3:CD004106.
51.
DucharmeFM, Ni ChroininM, GreenstoneI, LassersonTJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev, 2010; 4:CD005533.
52.
DucharmeFM, Ni ChroininM, GreenstoneI, LassersonTJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev, 2010; 5:CD005535.
53.
AdamsNP, LassersonTJ, CatesCJ, JonesP. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev, 2009; 2:CD002310.
54.
MolimardM, Le GrosV, RobinsonP, BourdeixI. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv, 2010; 23:91–95.
55.
ChungKF, CaramoriG, AdcockIM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol, 2009; 65:853–871.
56.
StoloffSW, StempelDA, MeyerJ, StanfordRH, Carranza RosenzweigJR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol, 2004; 113:245–251.
57.
MarceauC, LemiereC, BerbicheD, PerreaultS, BlaisL. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol, 2006; 118:574–581.
58.
DeleaTE, StanfordRH, HagiwaraM, StempelDA. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs*Curr Med Res Opin, 2008; 24:3435–3442.
59.
Bodzenta-LukaszykA, DymekA, McAulayK, MansikkaH. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med, 2011; 11:28.
60.
BenderBG, LongA, ParasuramanB, TranZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol, 2007; 98:322–328.
61.
HardingG, LeidyNK, MeddisD, KleinmanL, WagnerS, O'BrienCD. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin, 2009; 25:1563–1571.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
